A Phase I Study of PiggyBac CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Persistent and Relapsed B-cell Leukaemia and Lymphoma Post Allogeneic Stem Cell Transplantation (The CARTELL Study).

PiggyBac CD19 特异性嵌合抗原受体 T 细胞用于治疗同种异体干细胞移植后持续性和复发性 B 细胞白血病和淋巴瘤的 I 期研究（CARTELL 研究）。

• 批准号: nhmrc : GNT1102172
• 负责人: A/Pr Tracey O'Brien
• 金额: $ 35.76万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/phase-i-study-cartell-study/1346199
• 关键词: Phase; Study; PiggyBac; CD19; Specific

Most people with relapsed leukaemia and lymphoma after bone marrow transplant die of their disease. Inserting special genes into immune cells can enable them to kill leukaemia and lymphoma and has led to dramatic cures, but there is little experience in bone marrow transplant patients. We will make leukaemia and lymphoma specific immune cells from normal bone marrow transplant donors, then administer the immune cells to transplant patients to assess their safety and effectiveness.

大多数白血病和淋巴瘤复发的患者在骨髓移植后死于疾病。将特殊基因插入免疫细胞可以使它们杀死白血病和淋巴瘤，并导致戏剧性的治疗，但骨髓移植患者的经验很少。我们将从正常骨髓移植供体中制备白血病和淋巴瘤特异性免疫细胞，然后将免疫细胞用于移植患者，以评估其安全性和有效性。